76 Participants Needed

Virtual Group Speech Therapy for Head and Neck Cancer

Recruiting at 1 trial location
MC
HB
Overseen ByHouda Bahig, MD PhD
Age: 18+
Sex: Any
Trial Phase: Phase 1 & 2
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests a new kind of speech therapy for people with head and neck cancer. The therapy, called the Virtual Group Speech Pathology Intervention, occurs online in groups, guided by a patient who has undergone similar treatment. It aims to help patients adhere to their therapy and prevent swallowing problems that can arise after chemoradiotherapy. The trial seeks participants who have head or neck cancer, will receive specific radiation therapy, and speak French well enough to answer questions. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative therapy.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It is best to consult with the trial coordinators or your healthcare provider for guidance.

What prior data suggests that this virtual group speech therapy intervention is safe for patients with head and neck cancer?

Research shows that specific safety information for virtual group speech therapy for head and neck cancer patients is not yet available. However, this therapy is generally considered low-risk.

Similar studies have successfully used telehealth methods, such as virtual group sessions, with cancer patients. For example, in the Netherlands, patients used touch screen computers to report their feelings without encountering major problems. This suggests that virtual methods can be effective and well-accepted by patients.

As this trial is in its early stages, it focuses on ensuring the treatment is safe and manageable, making serious side effects unlikely at this point. Overall, while specific safety data for this therapy is limited, virtual interventions in similar contexts have been well-received and considered safe.12345

Why are researchers excited about this trial?

Researchers are excited about virtual group speech therapy for head and neck cancer because it offers a new way to deliver speech pathology care. Unlike traditional in-person sessions, this method uses virtual technology to connect patients in a group setting, guided by a patient partner. This approach not only makes therapy more accessible and convenient for patients who might struggle with travel or scheduling but also fosters a supportive community among participants. By leveraging digital platforms, this therapy has the potential to enhance engagement and improve outcomes for those recovering from head and neck cancer.

What evidence suggests that this virtual group speech therapy intervention is effective for head and neck cancer?

Research shows that online group speech therapy might benefit patients with head and neck cancer. In this trial, participants will join a virtual group speech therapy intervention led by a patient partner, simplifying participation. Past online health programs have successfully supported and educated cancer patients, suggesting this approach can help them adhere to treatment and avoid swallowing problems. Studies also indicate that online health services can improve access to care and increase patient understanding, potentially leading to better health outcomes. This could significantly enhance the quality of life for those undergoing chemoradiotherapy.12367

Are You a Good Fit for This Trial?

Adults over 18 with head or neck cancer starting chemoradiotherapy for cure can join. They need a radiation dose of at least 60 Grays and must speak French well enough for questionnaires. Those with distant cancer spread, planned total laryngectomy, prior severe swallowing issues, another simultaneous cancer, previous head/neck radiation, or significant cognitive impairments cannot participate.

Inclusion Criteria

My radiation therapy is planned to be 60 Grays or more.
I am 18 or older with head or neck cancer.
I am scheduled for chemoradiotherapy aimed at curing my condition.
See 1 more

Exclusion Criteria

I have been diagnosed with another cancer at the same time as my current one.
I have had serious swallowing problems checked by a speech therapist.
I have had radiation therapy to my head or neck.
See 3 more

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Chemoradiotherapy

Participants receive chemoradiotherapy treatment for head and neck cancer

6 weeks

Virtual Group Speech Therapy

Participants engage in a virtual, group-based speech therapy intervention guided by a patient partner

Concurrent with chemoradiotherapy

Follow-up

Participants are monitored for safety and effectiveness after treatment, including evaluation of nasogastric tube placement

6 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • Virtual Group Speech Pathology Intervention
Trial Overview The trial is testing the eG2 Intervention: a virtual group speech therapy guided by a patient partner to prevent swallowing difficulties in patients undergoing chemoradiotherapy for head and neck cancers. It aims to improve care quality and accessibility while optimizing healthcare resources.
How Is the Trial Designed?
1Treatment groups
Experimental Treatment
Group I: virtual group speech therapy intervention guided by a patient partnerExperimental Treatment1 Intervention

Virtual Group Speech Pathology Intervention is already approved in Canada for the following indications:

🇨🇦
Approved in Canada as eG2 Intervention for:

Find a Clinic Near You

Who Is Running the Clinical Trial?

Centre hospitalier de l'Université de Montréal (CHUM)

Lead Sponsor

Trials
389
Recruited
143,000+

Université du Québec à Trois-Rivières

Collaborator

Trials
48
Recruited
4,500+

Published Research Related to This Trial

In a study of 150 head and neck cancer patients over 12 months, better speech articulation was linked to a lower risk of dropout from the study, indicating that speech outcomes are crucial for patient retention.
Swallowing function did not show a significant relationship with dropout rates, suggesting that speech outcomes may be more critical in understanding patient experiences and the impact of surgical interventions.
Relating speech and swallow function to dropout in a longitudinal study of head and neck cancer.Colangelo, LA., Logemann, JA., Rademaker, AW., et al.[2007]
The Electronic Patient Visit Assessment (ePVA) is a reliable and valid web-based tool that effectively captures patient-reported symptoms and functional limitations in individuals with head and neck cancer, demonstrating a high completion rate (92%) among participants.
The ePVA correlates significantly with health-related quality of life (HRQoL) scores, indicating that patients with more symptoms and limitations experience worse HRQoL, thus supporting its potential for real-time clinical interventions to improve patient outcomes.
The usefulness of the Electronic Patient Visit Assessment (ePVA)© as a clinical support tool for real-time interventions in head and neck cancer.Van Cleave, JH., Fu, MR., Bennett, AV., et al.[2022]
A study of 128 non-laryngeal head and neck cancer survivors revealed that voice impairment is a common issue after treatment with radiotherapy (RT) or chemoradiotherapy (CRT), with significant findings of muscle tension and strain in the vocal cords.
The research highlighted that vocal handicap index (VHI) scores were significantly associated with dysphonia and treatment type, suggesting that targeted voice treatment regimens are needed to improve the quality of life for these patients.
Muscle Tension Dysphonia: A Sequeale of Chemoradiotherapy in Patients of Head and Neck Cancer.Sarin, V., Sarin, BC., Chatterjee, A., et al.[2023]

Citations

Innovative Patient-partner-guided Virtual Group Speech ...The innovation consists in offering a speech therapy intervention that is 1) virtual, 2) group-based (whereas it is usually individual) and 3) involves a ...
Virtual Group Speech Therapy for Head and Neck CancerThis project aims to study an innovative intervention, the eG2 Intervention, developed by speech-language pathologists at the Centre hospitalier de ...
Development of a Telehealth Intervention for Head and Neck ...This telehealth intervention provides support and education to patients undergoing treatment for head and neck cancers.
Feasibility and Acceptance of a Telehealth Intervention to ...Touch screen computers were successfully used in the Netherlands to collect quality of life and distress data from head and neck cancer patients [16].
Role of telemedicine in head neck cancerTelehealth interventions represent a possible novel approach to increase access to care across the cancer continuum, strengthen patients' knowledge and self- ...
Telemedicine and Virtual Interventions in Cancer ...The purpose of this review is to provide an overview of the practical applications of comprehensive cancer rehabilitation services through ...
ANZCTR - RegistrationThe purpose of this research is to test the effectiveness of using a computer simulation to personalise the force recommendations for jaw stretching and ...
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security